ANAB

Anaptysbio Inc

• Seeking Alpha·1d ago

  Forte Biosciences: 2026 Is Major Inflection Point For FB102

• Seeking Alpha·4d ago

  AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties

• Simply Wall St·4d ago

  Trade Alert: Independent Director Of AnaptysBio John Schmid Has Sold Stock

• Simply Wall St·6d ago

  Assessing AnaptysBio (ANAB) Valuation After New Share Buyback Plan And Canceled Equity Offering

• TipRanks·04/04 14:50

  Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB)

• Reuters·04/03 20:01

  AnaptysBio files Form 3 for director Susannah Gray, reporting no securities owned

• Simply Wall St·04/03 14:31

  Does AnaptysBio’s (ANAB) Buyback-Over-Equity Pivot Redefine Its Capital Discipline Narrative?

• Reuters·04/02 01:28

  AnaptysBio director John P. Schmid disposes shares worth $1.1 million

• Dow Jones·03/31 16:03

  AnaptysBio Is Maintained at Overweight by Piper Sandler

• Benzinga·03/31 15:53

  Piper Sandler Maintains Overweight on AnaptysBio, Raises Price Target to $95

• TipRanks·03/31 12:22

  Wedbush Remains a Buy on AnaptysBio (ANAB)

• TipRanks·03/31 10:51

  AnaptysBio price target raised to $95 from $67 at Piper Sandler

• Reuters·03/31 07:39

  U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks

• Reuters·03/31 03:15

  ANAPTYSBIO INC <ANAB.O>: PIPER SANDLER RAISES TARGET PRICE TO $95 FROM $67

• TipRanks·03/30 13:05

  AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup